← Back to Clinical Trials
Recruiting NCT07059689

NCT07059689 High-Flow Nasal Cannula vs. NIV After Extubation in Children Undergoing Heart Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07059689
Status Recruiting
Phase
Sponsor Indonesia University
Condition Heart Defects, Congenital
Study Type INTERVENTIONAL
Enrollment 114 participants
Start Date 2025-06-05
Primary Completion 2025-12

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
High Flow Nasal Cannula (HFNC)Non-Invasive Ventilation (NIV)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 114 participants in total. It began in 2025-06-05 with a primary completion date of 2025-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

High-Flow Nasal Cannula vs. NIV After Extubation in Children Undergoing Heart Surgery

Eligibility Criteria

Inclusion Criteria: * Patients under 18 years of age. * Post-cardiac surgery patients in the CICU of Cipto Mangunkusumo National General Hospital * Patients at high risk of extubation failure (e.g., young age, open sternotomy, mechanical ventilation \>48 hours). * Patients who pass the extubation readiness test and spontaneous breathing trial. Exclusion Criteria: * Diaphragmatic paralysis. * Decreased consciousness. * Neuromuscular disease. * Pneumothorax without drainage. * Airway obstruction. * Patients with a tracheostomy. * Unplanned extubation. * Patient received PEEP (Positive End-Expiratory Pressure) \>7 prior to extubation

Contact & Investigator

Central Contact

Head of Pediatric Emergency and Intensive Care Divison

✉ dr.yogiprawira@gmail.com

📞 +62811747363

Principal Investigator

Head of Pediatric Emergency and Intensive Care Divison

PRINCIPAL INVESTIGATOR

Indonesia University

Frequently Asked Questions

Who can join the NCT07059689 clinical trial?

This trial is open to participants of all sexes, up to 18 Years, studying Heart Defects, Congenital. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07059689 currently recruiting?

Yes, NCT07059689 is actively recruiting participants. Contact the research team at dr.yogiprawira@gmail.com for enrollment information.

Where is the NCT07059689 trial being conducted?

This trial is being conducted at Jakarta, Indonesia.

Who is sponsoring the NCT07059689 clinical trial?

NCT07059689 is sponsored by Indonesia University. The principal investigator is Head of Pediatric Emergency and Intensive Care Divison at Indonesia University. The trial plans to enroll 114 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology